Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series

Background: Information regarding the long-term outcome of enzyme replacement therapy (ERT) with recombinant human N-acetylgalactosamine 4-sulfatase (rhASB, galsulfase, Naglazyme®, BioMarin Pharmaceutical Inc.) for Taiwanese patients with mucopolysaccharidosis (MPS) VI is limited. Methods: Nine Taiw...

Full description

Bibliographic Details
Main Authors: Hsiang-Yu Lin, Chih-Kuang Chuang, Chung-Hsing Wang, Yin-Hsiu Chien, Yu-Mei Wang, Fuu-Jen Tsai, Yen-Yin Chou, Shio Jean Lin, Hui-Ping Pan, Dau-Ming Niu, Wuh-Liang Hwu, Yu-Yuan Ke, Shuan-Pei Lin
Format: Article
Language:English
Published: Elsevier 2016-06-01
Series:Molecular Genetics and Metabolism Reports
Subjects:
Cardiac hypertrophy
Diastolic dysfunction
Enzyme replacement therapy
Glycosaminoglycans
Mucopolysaccharidosis VI
Pulmonary function
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426916300283

Internet

http://www.sciencedirect.com/science/article/pii/S2214426916300283

Similar Items